CVS Health price target lowered to $94 from $102 at UBS

UBS lowered the firm’s price target on CVS Health (CVS) to $94 from $102 and keeps a Buy rating on the shares. UBS says CVS sentiment is "weary," and that the key debate is what 2023/2024 earnings will be, as existing guidance of $8.70-$8.90 and $9.00 is perceived to be at risk from a potential earlier close of the Oak Street Health (OSH) deal, the MA rate notice and lower COVID revenues.